Mirum Pharmaceuticals
MIRM
80.64
+1.39
+1.75%
Mirum Pharmaceuticals
US · MIRM
#2051 by market cap
Listed 2019
80.64
+1.39
+1.75%
Live - 5344 symbols - heartbeat 98s ago
· 2026-10-08 08:09
Pre-market
80.10
-0.67%
After-hours
80.64
0.00%
- Market cap
- 5.24B
- P/E (TTM)i
- -5.73
- P/Bi
- -500.87
- EPSi
- -0.47
- Div yieldi
- 0.00%
- 52W posi
- 26%
Reader sentiment
Are you bullish or bearish on MIRM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- Total institutional ownership fell 0.4 percentage points.
Institutional ownership
- Held by institutions
- 111.86% -0.43pp
- Institutions
- 403
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund77.60%
VC/PE Fund16.87%
Hedge Fund11.91%
Public Company2.96%
Individual/Insider1.29%
Private Company1.24%
Government Pension Fund0.64%
Sovereign Wealth Fund0.30%
Insurance Company0.27%
Top holders as of 2026-06-30
Frazier Life Sciences Management, LP
11.83% · 7.68M sh
Janus Henderson Group plc
9.10% · 5.91M sh
BlackRock
6.76% · 4.39M sh
FMR
5.65% · 3.67M sh
T. Rowe Price Group, Inc.
4.09% · 2.66M sh
Vanguard Capital Management, LLC
4.01% · 2.60M sh
Vanguard Portfolio Management, LLC
3.66% · 2.38M sh
State Street Global Advisors
3.34% · 2.17M sh
William Blair Investment Management, LLC
2.16% · 1.40M sh
Geode Capital Management, LLC
2.15% · 1.39M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 22 buys · 27 sells
| Name | Role | Stake |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 11.83% |
| Christopher Peetz | Chief Executive Officer | 0.59% |
| Michael Grey | Chairperson | 0.43% |
| Peter Radovich | Chief Operating Officer | 0.09% |
| Eric Bjerkholt | Chief Financial Officer | 0.07% |
| Joanne M. Quan | Chief Medical Officer | 0.03% |
| Laura Brege | Independent Director | 0.02% |
| Laurent Fischer | Independent Director | 0.02% |
| Timothy Walbert | Independent Director | 0.01% |
| Lon Cardon | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-20 | Rob Myers | Chief Medical Officer | Initial Statement of Beneficial | 0 | -- |
| 2026-09-13 | Eric Bjerkholt | Chief Financial Officer | Derivative Exercise and Sale | -9,943 | $98.37 |
| 2026-09-13 | Eric Bjerkholt | Chief Financial Officer | Intent to Sell (Form 144) | -9,943 | $98.37 |
| 2026-09-10 | Eric Bjerkholt | Chief Financial Officer | Derivative Exercise and Retained | +8,390 | -- |
| 2026-09-01 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -658 | $100.00 |
| 2026-08-31 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Sale | -30,000 | $2.94–98.91 |
| 2026-08-17 | Jolanda Howe | Senior VP & Global Controller | Derivative Exercise and Sale | -40,000 | $6.27–100.00 |
| 2026-08-10 | Eric Bjerkholt | Chief Financial Officer | Automatic Disposition | -6,001 | $99.90 |
| 2026-08-09 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Sale | -20,000 | $2.94–100.14 |
| 2026-08-02 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -1,840 | $105.29 |
| 2026-07-05 | Eric Bjerkholt | Chief Financial Officer | Automatic Disposition | -5,000 | $121.67–124.94 |
| 2026-07-05 | Christopher Peetz | Chief Executive Officer | Derivative Exercise and Sale | -20,000 | $2.94–124.79 |
| 2026-06-30 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -2,721 | $120.00 |
| 2026-06-16 | Jolanda Howe | Senior VP & Global Controller | Automatic Disposition | -2,594 | $101.95 |
| 2026-06-14 | Patrick Heron | Independent Director | Other Derivative Acquisition | +1,980 | -- |
| 2026-06-14 | Patrick Heron | Independent Director | Other Derivative Acquisition | +3,772 | $101.00 |
| 2026-06-14 | Laura Brege | Independent Director | Other Derivative Acquisition | +1,980 | -- |
| 2026-06-14 | Laura Brege | Independent Director | Other Derivative Acquisition | +3,772 | $101.00 |
| 2026-06-14 | Michael Grey | Chairperson | Other Derivative Acquisition | +1,980 | -- |
| 2026-06-14 | Michael Grey | Chairperson | Other Derivative Acquisition | +3,772 | $101.00 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:09:09 · For reference only, not investment advice and not tailored to your situation.